Furthermore, patients with HER2+ limited metastatic (less extensive / small‐volume burden of metastatic disease) or extensive loco‐regional recurrent disease, or who had metastatic disease but were exceptional responders (achieving a long‐lasting complete response), had a cure rate of more than 30%.6, 7. Here, ERBB2 is linked to metastatic neoplasm.